Botox Rival Cites FDA Delay for Possible Going-Concern Statement

Revance Therapeutics, whose potential Botox rival ran into resistance from the Food & Drug Administration, says it has enough cash to keep operating for at least 12 months. But in a regulatory filing late Tuesday, Revance says it may need to raise capital and “absent deferring and reducing certain costs previously planned as well as other mitigating actions, the commercial launch delay and its impact on our capital resources would raise substantial doubt with respect to our ability to meet our obligations to continue as a going concern.”

• As previously reported, the FDA said in an October letter ...